197 related articles for article (PubMed ID: 30036377)
1. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
Rhyasen GW; Yao Y; Zhang J; Dulak A; Castriotta L; Jacques K; Zhao W; Gharahdaghi F; Hattersley MM; Lyne PD; Clark E; Zinda M; Fawell SE; Mills GB; Chen H
PLoS One; 2018; 13(7):e0200826. PubMed ID: 30036377
[TBL] [Abstract][Full Text] [Related]
2. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
3. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
4. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
Front Immunol; 2020; 11():89. PubMed ID: 32184777
[TBL] [Abstract][Full Text] [Related]
5. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
6. BRD4 facilitates replication stress-induced DNA damage response.
Zhang J; Dulak AM; Hattersley MM; Willis BS; Nikkilä J; Wang A; Lau A; Reimer C; Zinda M; Fawell SE; Mills GB; Chen H
Oncogene; 2018 Jul; 37(28):3763-3777. PubMed ID: 29636547
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
8. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
9. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
Baratta MG; Schinzel AC; Zwang Y; Bandopadhayay P; Bowman-Colin C; Kutt J; Curtis J; Piao H; Wong LC; Kung AL; Beroukhim R; Bradner JE; Drapkin R; Hahn WC; Liu JF; Livingston DM
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):232-7. PubMed ID: 25535366
[TBL] [Abstract][Full Text] [Related]
10. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
11. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.
Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S
Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834
[TBL] [Abstract][Full Text] [Related]
12. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
[TBL] [Abstract][Full Text] [Related]
13. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
14. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
[TBL] [Abstract][Full Text] [Related]
15. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
[TBL] [Abstract][Full Text] [Related]
17. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.
Villar-Prados A; Wu SY; Court KA; Ma S; LaFargue C; Chowdhury MA; Engelhardt MI; Ivan C; Ram PT; Wang Y; Baggerly K; Rodriguez-Aguayo C; Lopez-Berestein G; Ming-Yang S; Maloney DJ; Yoshioka M; Strovel JW; Roszik J; Sood AK
Mol Cancer Ther; 2019 Feb; 18(2):421-436. PubMed ID: 30420565
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
20. Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.
Yeh TC; O'Connor G; Petteruti P; Dulak A; Hattersley M; Barrett JC; Chen H
Clin Cancer Res; 2017 Feb; 23(4):1025-1035. PubMed ID: 28073847
[No Abstract] [Full Text] [Related]
[Next] [New Search]